Neurocrine Biosciences to Participate at Investor Conferences in December
Rhea-AI Summary
Neurocrine Biosciences (NBIX) has announced its participation in two major investor conferences this December. The company will present at The 7th Annual Evercore HealthCONx Conference on December 3 at 10:50 a.m. ET in Coral Gables, Florida, and Citi's 2024 Global Healthcare Conference on December 4 at 1:45 p.m. ET in Miami.
The presentations will be accessible via webcast on Neurocrine's website, with replays available for approximately one month. The company, focused on neuroscience and biopharmaceuticals, develops treatments for neurological, neuroendocrine, and neuropsychiatric disorders, with FDA-approved treatments for conditions including tardive dyskinesia, Huntington's disease chorea, endometriosis, and uterine fibroids.
Positive
- None.
Negative
- None.
News Market Reaction – NBIX
On the day this news was published, NBIX declined 1.03%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
The 7th Annual Evercore HealthCONx Conference on December 3
Citi's 2024 Global Healthcare Conference on December 4
- The 7th Annual Evercore HealthCONx Conference at 10:50 a.m. Eastern Time on Tuesday December 3, 2024 in
Coral Gables, Florida . - Citi's 2024 Global Healthcare Conference at 1:45 p.m. Eastern Time on Wednesday December 4, 2024 in
Miami .
The live presentations will be webcast and may be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcasts will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X (Formerly Twitter) and Facebook. (*in collaboration with AbbVie)
NEUROCRINE BIOSCIENCES, NEUROCRINE, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. The Neurocrine logo is a trademark of Neurocrine Biosciences, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-participate-at-investor-conferences-in-december-302316899.html
SOURCE Neurocrine Biosciences, Inc.
FAQ
When is Neurocrine Biosciences (NBIX) presenting at the Evercore HealthCONx Conference 2024?
Where can I watch Neurocrine Biosciences' (NBIX) December 2024 investor conference presentations?
What medical conditions does Neurocrine Biosciences (NBIX) currently have FDA-approved treatments for?
When is Neurocrine Biosciences (NBIX) presenting at Citi's 2024 Global Healthcare Conference?
